2023 North America Conference on Lung Cancer (NACLC) - Posters and Abstracts-PP01.34 (Poster) Quantifying Minimal Residual Disease in Patients with Limited Stage Small Cell Lung Cancer

PP01.34 (Poster) Quantifying Minimal Residual Disease in Patients with Limited Stage Small Cell Lung Cancer

Pdf Summary

The document discusses the use of ctDNA analysis for minimal residual disease (MRD) assessment in patients with limited-stage small cell lung cancer (LS-SCLC). The study found that both on-treatment and post-treatment ctDNA analysis can provide insight into clinical outcomes in these patients. However, larger datasets are needed to validate these findings and determine the optimal timepoint for MRD assessment. <br /><br />The hope is that this research will lead to prospective trials incorporating ctDNA as a biomarker in the management of SCLC patients. The document includes several figures illustrating the results of the study. One figure shows the radiographic recurrence or death based on ctDNA detection after completion of curative intent therapy. The median time to recurrence or death was shorter in the ctDNA positive group compared to the ctDNA negative group.<br /><br />Another figure shows the characteristics of the LS-SCLC patients analyzed by the Guardant Reveal assay. This includes patient age, gender, race, and TNM stage. Additional figures outline the assay workflow and the model of detectable tumor molecules in a 30ng cell-free DNA sample.<br /><br />The document also provides clinical data for the patients, including treatment modality and prophylactic cranial irradiation. The median survival for patients with ctDNA detected was shorter compared to those without ctDNA detected.<br /><br />In conclusion, the study demonstrates the potential of ctDNA analysis as a valuable tool for MRD assessment in LS-SCLC patients. However, further research and validation are needed to fully understand its clinical implications and determine the best approach for integrating ctDNA testing into patient management.

Asset Subtitle

Daenielle Lang

Keywords

ctDNA analysis

MRD assessment

LS-SCLC

clinical outcomes

biomarker

radiographic recurrence

Guardant Reveal assay

TNM stage

treatment modality

patient management